Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Imfinzi, Lynparza On Track To India Debut

Executive Summary

AstraZeneca, which recently committed to scaling up investments in India, appears on course to bringing two key new anticancers to the country, including the PD-1/L1 inhibitor Imfinzi. Pricing aspects for the products in what is a largely out-of-pocket market are, however, expected to be decisive.

You may also be interested in...



Will 'Financial Toxicity’ Weigh Down 1L NSCLC Win For Tagrisso In India?

The price factor could potentially shrink the patient pool in first line non-small cell lung cancer for Tagrisso in largely out-of-pocket markets like India, though AstraZeneca has put in place a patient assistance program in this market for those can’t afford the medicine.

Why Pharma Doesn't Always Keep Phase IV Promises In India

Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.

AstraZeneca Bolstering India Play With $90m Investment Plan

AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel